My ePortfolio Register   

ESMO 2017 /
Pembrolizumab falls short of endpoints in KEYNOTE 40

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 1011

Dr Ezra Cohen - UC San Diego Health, San Diego, USA

Dr Cohen speaks with ecancer at the ESMO 2017 Congress about the phase III KEYNOTE-040 trial looking at pembrolizumab vs standard of care for recurrent or metastatic head and neck squamous cell carcinoma. 

While the overall survival of patients receiving PD-1 immunotherapy is improved, Dr Cohen reports that this improval falls just short of the trials threshold for statistical significance.

He also notes that grade 3-5 adverse events were reduced in the pembrolizumab arm, and that further investigations or stratification of patients by PD-L1 expression may improve on these results.

Read more about the results here.

Dr Cohen also spoke with ecancer about the SCORES trials of durvalumab combinations, here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence